NBC Securities Inc. Purchases 2,672 Shares of Repligen Co. (NASDAQ:RGEN)

NBC Securities Inc. increased its position in shares of Repligen Co. (NASDAQ:RGEN) by 133,600.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,674 shares of the biotechnology company’s stock after acquiring an additional 2,672 shares during the period. NBC Securities Inc.’s holdings in Repligen were worth $340,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of RGEN. Mirae Asset Global Investments Co. Ltd. grew its position in Repligen by 46.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,629 shares of the biotechnology company’s stock worth $2,679,000 after acquiring an additional 5,913 shares during the last quarter. Stephens Investment Management Group LLC grew its position in Repligen by 7.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock worth $77,267,000 after acquiring an additional 37,057 shares during the last quarter. Angeles Wealth Management LLC bought a new stake in Repligen during the 4th quarter worth $220,000. Louisiana State Employees Retirement System grew its position in Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock worth $2,087,000 after acquiring an additional 100 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Repligen by 79.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock worth $65,395,000 after acquiring an additional 203,011 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 1.3%

Shares of NASDAQ:RGEN opened at $128.30 on Friday. The company has a market capitalization of $7.21 billion, a price-to-earnings ratio of -251.57, a P/E/G ratio of 4.54 and a beta of 1.10. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The business’s 50-day moving average is $127.27 and its 200-day moving average is $143.38. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. During the same period in the prior year, the business earned $0.28 EPS. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. Equities research analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on RGEN shares. Canaccord Genuity Group reduced their price objective on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research report on Wednesday, April 16th. TD Cowen started coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 target price on the stock. Royal Bank of Canada cut their target price on Repligen from $202.00 to $189.00 and set an “outperform” rating on the stock in a report on Wednesday, April 30th. HC Wainwright reaffirmed a “buy” rating and set a $180.00 target price on shares of Repligen in a report on Monday, May 5th. Finally, JPMorgan Chase & Co. cut their target price on Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $173.25.

Insider Buying and Selling

In related news, Director Margaret Pax acquired 250 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is owned by company insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.